Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Xenetic Biosciences, Inc. (XBIO)

2.1000 0.0000 (0.00%)
At close: October 14 at 4:00:00 PM EDT
2.1000 0.0000 (0.00%)
Pre-Market: 9:11:37 AM EDT
Chart Range Bar
Loading chart for XBIO
  • Previous Close 2.1000
  • Open 2.1150
  • Bid 1.5900 x 200
  • Ask 2.8600 x 200
  • Day's Range 2.0900 - 2.1300
  • 52 Week Range 1.8700 - 4.9390
  • Volume 12,567
  • Avg. Volume 87,409
  • Market Cap (intraday) 4.921M
  • Beta (5Y Monthly) 2.20
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1400
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

www.xeneticbio.com

2

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More
Xenetic Biosciences: Q3 Earnings Snapshot

Xenetic Biosciences: Q3 Earnings Snapshot

Performance Overview

Trailing total returns as of 10/14/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

XBIO
3.23%
S&P 500 (^GSPC)
12.76%

1-Year Return

XBIO
58.58%
S&P 500 (^GSPC)
16.17%

3-Year Return

XBIO
50.45%
S&P 500 (^GSPC)
78.36%

5-Year Return

XBIO
88.77%
S&P 500 (^GSPC)
73.92%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 573.89k
Earnings -433.68k
Profit Margin -75.57%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-500K
0
500K
-140.0%
-120.0%
-100.0%
-80.0%
-60.0%

Statistics

View More

Valuation Measures

Annual
As of 9/21/2026
  • Market Cap

    5.86M

  • Enterprise Value

    -613.81k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.59

  • Price/Book (mrq)

    0.96

  • Enterprise Value/Revenue

    0.15

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -75.91%

  • Return on Assets (ttm)

    -26.80%

  • Return on Equity (ttm)

    -47.04%

  • Revenue (ttm)

    3.26M

  • Net Income Avi to Common (ttm)

    -2.48M

  • Diluted EPS (ttm)

    -1.1400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.47M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.17M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.1000 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: